Huntsman's Bold Asset Shift: Pain Now, Profit Later?

Huntsman Corporation (HUN) has taken a decisive step into 2025 with its $75 million impairment charge tied to the closure of its Moers, Germany, plant—a move that underscores a strategic pivot to prioritize high-margin segments and cost discipline. While this non-cash charge has drawn scrutiny, the decision reflects a calculated trade-off between short-term pain and long-term profitability. For investors, the question is whether this restructuring sets the stage for an EBITDA recovery that could push shares toward Wall Street's $14.46 average target—a 23% premium to current levels.

The Impairment Charge: A Necessary Sacrifice

The write-down of the Moers facility, announced in Q2 2025, stems from Huntsman's broader review of its European operations. The plant, part of the loss-making Maleic Anhydride business, will cease operations by year-end, with European customers rerouted to lower-cost North American facilities in Pensacola, Florida, and Geismar, Louisiana. While the $75 million charge will weigh on Q2 earnings, it is critical to note that this is a one-time, non-cash expense that does not impact liquidity. With $1.3 billion in combined cash and borrowing capacity, Huntsman is financially fortified to weather this adjustment.

The closure also aligns with a strategic retreat from underperforming assets. The European Maleic Anhydride business posted a $10 million EBITDA loss in 2024, underscoring the need to redirect resources to higher-margin areas. This move positions Huntsman to focus on its core strengths: polyurethanes and specialty chemicals, particularly in the lucrative MDI (methylene diphenyl diisocyanate) market.

The MDI Market: Early Signs of Recovery

Huntsman's MDI segment, while not explicitly detailed in Q1 earnings, is central to its EBITDA recovery narrative. CEO Peter Huntsman noted “early signs of recovery” in MDI pricing, with Chinese polymeric MDI (PMDI) prices hitting three-year highs and U.S. producers announcing price hikes for the first time in two years. These trends signal an end to the prolonged destocking cycle, driven by improving demand in construction and automotive sectors.

The Geismar MDI splitter project, nearing completion, is poised to deliver $15 million in annual EBITDA by 2025. Combined with investments in semiconductor-grade amines—targeting $5–7 million in 2025 EBITDA—these initiatives highlight Huntsman's focus on high-margin, growth-oriented markets.

Cost Discipline and Liquidity: A Solid Foundation

Huntsman's restructuring extends beyond asset closures. The company aims to realize $60 million in annual cost savings through supply chain optimizations and reduced SG&A expenses. Notably, its North American rerouting strategy reduces logistics costs while leveraging lower energy prices in the U.S.

The dividend, a 7.5% yield at $0.25 per share, further signals confidence in cash flow. Despite Q1's $5 million net loss, adjusted EBITDA held steady at $72 million, with Q2 guidance of $60–90 million reflecting management's cautious optimism.

Balancing Risk and Reward

The path to EBITDA recovery is not without hurdles. Europe's overcapacity and regulatory uncertainty remain a drag, while U.S.-China trade tensions could dampen demand. However, Huntsman's liquidity buffer and focus on margin-expanding projects mitigate these risks. Analysts at BofA Securities recently downgraded the stock to Neutral, citing delayed earnings recovery, but Fitch Ratings highlighted improving credit metrics as Huntsman trims debt. With shares down 49% year-to-date, the current price of $11.70 offers a compelling entry point if EBITDA rebounds as guided.

Conclusion: A Strategic Inflection Point

Huntsman's impairment charge is a costly but necessary step to realign its portfolio with high-margin opportunities. The Moers closure, coupled with MDI recovery and cost discipline, positions the company to deliver EBITDA growth in 2025 and beyond. With liquidity intact and Wall Street pricing in upside potential, now may be the time to act: Huntsman's pain today could translate into profit for investors tomorrow.

Investment Thesis: Buy HUN at $11.70, targeting $14.46. Risk: Geopolitical shocks, further EBITDA misses, or continued underperformance of earnings-based timing strategies. Reward: EBITDA recovery and dividend resilience.

Historical data shows that a buy-and-hold strategy triggered by earnings announcements from 2020 to 2025 underperformed, yielding an average return of -3.96% and a maximum drawdown of -60.93%, underscoring the risks of timing entries based on quarterly reports.

This article is for informational purposes only and does not constitute financial advice.